Trial reportJournal of molecular neuroscience : MN2025
Efficacy and Safety of Electroacupuncture Combined with Agomelatine Tablets Therapy in Treating Insomnia After Stroke.
Trial report in Journal of molecular neuroscience : MN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sleep disorders in stroke rehabilitation: mechanisms, impacts, and multidisciplinary management - a narrative review.Frontiers in neurology · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insomnia, a common complication following stroke, significantly impairs patients' clinical outcomes. Electroacupuncture (EA), an advanced acupuncture technique, has demonstrated efficacy in alleviating insomnia symptoms. Agomelatine (AT), a melatonin receptor agonist, is widely utilized for depression management. This study aimed to evaluate the therapeutic effects of combined EA + AT therapy for post-stroke insomnia. A total of 120 stroke-related insomnia patients were randomly assigned to three intervention groups (n = 40 each): EA therapy, AT treatment, and EA + AT combination therapy. Sleep efficiency and cognitive function were comprehensively assessed using the Cardiopulmonary Coupling-based sleep quality evaluation system, Montreal Cognitive Assessment (MoCA), and National Institutes of Health Stroke Scale (NIHSS). The results revealed that all three interventions significantly enhanced sleep efficiency (EA: 78.23 ± 4.19; AT: 75, 5; EA + AT: 80.97 ± 4.21) and MoCA scores (EA: 24, 2; AT: 24, 2; EA + AT: 27, 2), with the combination therapy showing superior effectiveness. Similarly, NIHSS scores exhibited marked reduction across all treatment groups (EA: 6, 2; AT: 7, 2), particularly in the EA + AT combination cohort (EA + AT: 4, 3). Notably, post-treatment analysis revealed significant positive correlations between sleep efficiency and MoCA scores in all groups, with the strongest correlation observed in the AT group (r = 0.87). These findings demonstrate that EA + AT combination therapy outperforms monotherapies in treating post-stroke insomnia. In conclusion, this study establishes EA + AT as an effective intervention for improving both sleep quality and cognitive function in stroke-related insomnia patients, offering a promising therapeutic strategy for this clinical condition.
Indexed as
Identifiers
40782216What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.